In patients with diabetes and multivessel CAD, ticagrelor fails to meet noninferiority criteria compared with prasugrel at 1-year post-PCI.

In a recent video interview with Applied Clinical Trials, Marc Buyse, ScD, founder and CEO of IDDI, discussed how growing trial complexity is creating new challenges for data conf ...

The FDA declined to endorse leucovorin as a treatment for autism, but approved the drug to treat cerebral folate deficiency, ...

Cigarette smoking remains the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year and costing the nation over $600 billion annually in ...

Revised 3.2. Measurement of TC, LDL-C, HDL-C, TG, and Non–HDL-C COR 2a: For adults with an LDL-C level <70 mg/dL (<1.8 mmol/L), measurement of direct LDL-C or modified LDL-C estimate is reasonable to ...

Researchers explore the links between birth control and depression, highlighting potential risks among adolescents.

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

mCommunicable Disease Prevention and Control, Ministry of Health, Kampala, Uganda nNon-Communicable Diseases Control Programme, Ministry of Health, Kampala, Uganda ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Introduction With the rapid ageing of the global population, the number of persons with dementia (PwDs) is increasing, placing substantial psychological and physical burdens on family caregivers.